STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer

被引：0
|
作者：
Abdi Ghaffari
Nichole Peterson
Kasra Khalaj
Natasha Vitkin
Andrew Robinson
Julie-Ann Francis
Madhuri Koti
机构：
[1] Queen’s University,Department of Biomedical and Molecular Sciences
[2] Queen’s University,Department of Obstetrics and Gynecology, Kingston Health Sciences Center
[3] Queen’s University,Department of Oncology, Kingston Health Sciences Center
[4] Queen’s University,Cancer Biology and Genetics, Queen’s Cancer Research Institute
来源：
British Journal of Cancer | 2018年 / 119卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：440 / 449
页数：9
相关论文
共 50 条
  • [31] Anti-PD-1 immune checkpoint blockade-based therapy using pembrolizumab in a patient with high-grade glioblastoma
    Payandeh, Mehrdad
    Karami, Afshin
    Bavarsad, Sareh Bakhshandeh
    Asadollahi, Samira
    Jafari, Mahboobeh
    Karami, Noorodin
    [J]. BIOMEDICAL RESEARCH AND THERAPY, 2023, 10 (05): : 5680 - 5685
  • [32] Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer
    Shakfa, Noor
    Li, Deyang
    Conseil, Gwenaelle
    Lightbody, Elizabeth D.
    Wilson-Sanchez, Juliette
    Hamade, Ali
    Chenard, Stephen
    Jawa, Natasha A.
    Laight, Brian J.
    Afriyie-Asante, Afrakoma
    Tyryshkin, Kathrin
    Koebel, Martin
    Koti, Madhuri
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (04)
  • [33] PD-L1 Expression in High-Grade Serous and Clear Cell Ovarian Cancer
    Ljubiša Jovanović
    Andja Ćirković
    Milena Jović
    Radmila Janković
    [J]. Indian Journal of Gynecologic Oncology, 2022, 20
  • [34] STAT1 associated immune checkpoint expression and immune cell localization represent adaptive immune resistance in high-grade serous ovarian cancer
    Li, Deyang
    Vidotto, Thiago
    Shakfa, Noor
    Afriyie-Asante, Afrakoma
    Peterson, Nichole
    de Ladurantaye, Manon
    Mes-Masson, Anne-Marie
    Francis, Julie-Ann
    Koti, Madhuri
    [J]. JOURNAL OF IMMUNOLOGY, 2021, 206
  • [35] PD-L1 Expression in High-Grade Serous and Clear Cell Ovarian Cancer
    Jovanovic, Ljubisa
    Cirkovic, Andja
    Jovic, Milena
    Jankovic, Radmila
    [J]. INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2022, 20 (04)
  • [36] Molecular Biomarkers of Response to PD-1/PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
    Tu, Megan M.
    Ng, Terry L.
    De Jong, Horns C.
    Zuiverloon, Tahlita C. M.
    Fazzari, Francesco G. T.
    Theodorescu, Dan
    [J]. BLADDER CANCER, 2019, 5 (02) : 131 - 145
  • [37] Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer
    Kim, Hyun-Soo
    Kim, Ji-Ye
    Lee, Yong Jae
    Kim, So Hee
    Lee, Jung-Yun
    Nam, Eun Ji
    Kim, Sunghoon
    Kim, Sang Wun
    Kim, Young Tae
    [J]. GYNECOLOGIC ONCOLOGY, 2018, 151 (03) : 414 - 421
  • [38] Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer
    Dahl, Erika S.
    Buj, Raquel
    Leon, Kelly E.
    Newell, Jordan M.
    Imamura, Yuka
    Bitler, Benjamin G.
    Snyder, Nathaniel W.
    Aird, Katherine M.
    [J]. MOLECULAR CANCER RESEARCH, 2019, 17 (08) : 1710 - 1720
  • [39] BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines
    Shen, Yen Ting
    Evans, James C.
    Zafarana, Gaetano
    Allen, Christine
    Piquette-Miller, Micheline
    [J]. MOLECULAR PHARMACEUTICS, 2018, 15 (07) : 2742 - 2753
  • [40] Ovarian Cancer Response Scoring (OCRS): Validation of a system to quantify histopathological response to neoadjuvant chemotherapy in high-grade serous ovarian cancer
    Singh, N.
    Said, I.
    Faruqi, A.
    Gilks, B.
    Le, N.
    Boehm, S.
    [J]. VIRCHOWS ARCHIV, 2014, 465 : S40 - S40
12345